Jain Global LLC Grows Position in Dyne Therapeutics, Inc. $DYN

Jain Global LLC boosted its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 8.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 644,082 shares of the company’s stock after buying an additional 47,915 shares during the period. Jain Global LLC owned 0.45% of Dyne Therapeutics worth $8,148,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DYN. Chung Wu Investment Group LLC purchased a new position in shares of Dyne Therapeutics during the third quarter worth approximately $30,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Dyne Therapeutics by 25.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after purchasing an additional 1,109 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Dyne Therapeutics by 11.1% in the second quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock valued at $91,000 after purchasing an additional 955 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Dyne Therapeutics by 275.1% during the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after purchasing an additional 7,697 shares during the last quarter. Finally, Prudential Financial Inc. acquired a new stake in shares of Dyne Therapeutics during the second quarter worth $111,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Insider Activity

In related news, Director Brian S. Posner bought 3,000 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, March 6th. The shares were purchased at an average price of $15.06 per share, with a total value of $45,180.00. Following the purchase, the director owned 11,500 shares in the company, valued at $173,190. This represents a 35.29% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 20.77% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wall Street Zen downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 28th. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Morgan Stanley lowered their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. HC Wainwright dropped their target price on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Finally, Chardan Capital reissued a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.14.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $18.13 on Tuesday. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $2.99 billion, a P/E ratio of -5.12 and a beta of 1.34. The firm has a 50-day moving average price of $16.99 and a two-hundred day moving average price of $17.35. Dyne Therapeutics, Inc. has a twelve month low of $6.36 and a twelve month high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.02). As a group, research analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.